QNET, one of Asia’s leading direct selling company, offers SHARP-QNET ZENsational Air purifier and Plasmacluster ion products with Sharp’s patented Plasmacluster ion technology (PCI) in the device to help deactivate airborne novel coronavirus (SARS-CoV-2), when exposed to the technology for approximately 30 seconds by 90%. The PCI Technology has been certified by over 30 global Institutes, including IIT Delhi. The study on efficacy of PCI technology in deactivating coronavirus was undertaken by Japanese professors of Nagasaki and Shimane University.
Commenting on the recent study conducted in September 2020, and the world’s first claim by Sharp, Rishi Chandiok, Regional Director (South Asia) QNet Ltd. said, “This is a successful breakthrough in today’s scenario where companies and governments are trying to find ways to contain the spread of Coronavirus around the globe. QNET congratulates Sharp for being the world’s first company to have patent Plasmacluster® ion technology, which guarantees to deactivate 90 % of the coronavirus. Most importantly this effective study will strengthen our five long years of relationship with Sharp and help empower our customers with better health through cutting edge technology products in QNET India portfolio.”
SHARP-QNet ZENsational Air Purifier has Sharp’s patented Plasmacluster® ion technology, an integrated humidifier, and 7 Intelligent-Detection Modes, the first of its kind in this category. The co-branded air purifier is the second product partnership between QNET and SHARP. The product models – SHARP-QNET Plasmacluster® Ion Air Purifier and ZENsational Air purifier are QNET’s top-selling products in recent years in India. The ZENsational Air purifier has an intelligent sensor system that monitors and indicates the dust, odour, haze, temperature, and humidity conditions of the room. Based on the requirement, the sensors detect the need and automatically adjust the function, resulting in energy efficiency. QNET’s distribution channel comprises a strong network of over 5 lakh distributors spread across key cities in India.
This path breaking achievement was accomplished in collaboration with internationally respected authorities on infectious diseases and research, through – National Research Center for the Control and Prevention of Infectious Diseases/Institute of Tropical Medicine, Nagasaki University, Japanese Society for Virology, Department of Microbiology, and Shimane University.
Sharp has been demonstrating the effectiveness of Plasmacluster technology by working in collaboration with independent third-party research organizations around the world. So far, numerous independent research organizations have proven its clinical efficacy in suppressing the activity of harmful substances including new pandemic influenza viruses, drug-resistant bacteria, and mite allergens, as well as in reducing bronchial inflammation levels in children with asthma.